PER-039-01已完成未知
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (HCC) USING PEG-INTERFERON ALPHA 2B AND RIBAVIRINE
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with HCC woman or adult male, 18 to 70 years of age.
- •Liver disease compensated with the following minimum hematological and biochemical criteria:
- •- Hemoglobin> 13 g / day for men,> 12 g / day for women
- •- White blood cell count> 3,000 / mm ^
- •- Granulocyte count> 1,500 / mm ^
- •- Platelets> 100,000 / mm ^
- •- Direct and indirect bilirubin within normal limits (unless factors unrelated to hepatitis such as Gilbert´s disease explain an elevation of indirect bilirubin.In such cases indirect bilirubin should be <3.0 mg / dl or < 51.3 umol / 1)
- •- Albumin within normal limits
- •- Serum creatinine within normal limits
- •Fasting glucose should be 70-115 mg / dl. Results between 115-140 mg / dl require repeating the fasting glucose test to be <140 mg / dl and Hb A1c (glycosylated hemoglobin) <8.5%. Hemoglobin Ale should be <8.5% for diabetic patients (even when in control with diet or medication).
- •Thyroid Stimulating Hormone (TSH), within normal limits (Patients requiring medication to maintain TSH levels in the normal range will be eligible if they meet all other inclusion criteria).
- •Antinuclear Antibodies (ANA) <1: 160
- •Alphafetoprotein value within normal limits, obtained within the year prior to entry into the study.
- •HTV negative (positive ELISA results will be confirmed by Western n Blot)
- •The patient must be seronegative for the surface antigen (HBsAg) of Hepatitis B.
- •Elevated TGP before entering the study
- •Sero positive for hepatitis C virus by bDNA or PCR / RNAVHC assay.
- •Liver biopsy (optional) within 12 months prior to admission to this study with a pathology report confirming that the histological diagnosis is consistent with chronic hepatitis.
- •If there is a history of diabetes or hypertension, an eye examination is indicated prior to therapy
- •Reconfirmation that sexually active women with a chance of getting pregnant are practicing an adequate method of contraception (intra uterine device, diaphragm + spermicide or condom + spermicide, oral contraceptives, progesterone implant rods (Norplant), medroxyprogesterone acetate (Depo-Provera ), surgical sterilization, or monogamous relationship with a male partner who has had a vasectomy) during the period of treatment and for 6 months after the discontinuation of therapy.
- •Reconfirmation that sexually active men are using acceptable methods of contraception (vasectomy, condom + spermicide, monogamous relationship with a woman partner who practices an acceptable method of contraception) during the period of treatment and for 6 months after discontinuation of therapy . Female patients should not breastfeed during the period of treatment.
排除标准
- •Patients older than 70 years of age
- •Pregnant or lactating women
- •Suspected hypersensitivity to interferon, PEG-interferon or ribavirin.
- •Participation in any other clinical trial within 30 days prior to entering this study.
- •Treatment with any investigational drug within 30 days prior to entering this study.
- •Patients with organ transplants other than cornea and hair transplant
- •Any cause of liver disease based on the patient´s history and biopsy (when required) other than chronic hepatitis C
- •Known positivity of HIV
- •Patients with hemophilia or any hemoglobinopathy including but not limited to thalassemia major and minor.
- •Any known pre-existing medical condition that could interfere with the patient´s participation and its completion in the study
- •Any medical condition that requires, or will likely require, during the course of the study, a chronic, systematic administration of steroids.
- •Clinical Drop
- •Substance abuse, such as alcohol (> 80 g / day), IV drugs. or drugs that are inhaled. If the patient has a history of substance abuse, to be considered for inclusion in the study, the patient must have abstained from using the substance of abuse for at least 2 years. Patients who received methadone within the last 2 years are also excluded.
- •Patients with significant abnormalities in the retina.
- •Patients who do not wish to be advised or who do not wish to abstain from alcohol consumption.
- •Any other condition that in the opinion of the investigator would make the patient unfit for inclusion, or that could interfere with the patient´s participation to complete the study
研究者
相似试验
已完成
不适用
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C USING ALFA 2B INTERFERON ASSOCIATED WITH RIBAVIRINE, COMPARING IT WITH THE SAME SCHEME PREVIOUS FROM DAILY ADMINISTRATION FOR 2 WEEKS OF ALFA 2 B INTERFEROPER-014-98SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B (HCB) USING PEG-INTERFERON ALPHA 2BPER-040-01SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
Spirulina Platensis in the Treatment of Chronic Hepatitis C Virus (HCV) InfectioACTRN12610000958088Abbass Helmy Charity60
已完成
2 期
A pilot phase II open-label study of oglufanide disodium in patients with chronic hepatitis CChronic hepatitis CInfection - Other infectious diseasesACTRN12607000418471Implicit Bioscience Pty Ltd17
已完成
不适用
Retreatment of chronic hepatitis C patients with pegylated interferon, ribavirin and amantadine; A pilot study to establishif initial drop in viral load is predictive for sustained virological response.Chronic hepatitis C infectionNL-OMON27702Schering-Plough61